Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. PAI Partners divests ADB Safegate
Mandate

PAI Partners divests ADB Safegate

August 03, 2017

Vinge together with Willkie Farr & Gallagher have advised the French private equity fund PAI Partners in conjunction with their sale of the ADB Safegate Group to The Carlyle Group.

The ADB Safegate Group is a leading supplier of airfield solutions which provide management systems for aircraft docking, management systems for terminals, airfield lighting and airfield management systems globally. Vinge advised ADB in conjunction with its acquisition of Safegate in 2016.

Vinge’s team consisted of, among others, partner Jonas Bergström, associates Carl Sander, Michaela Cronemyr, Samra Baytar (M&A), Linn Adelwald (Financial Arrangements), Lova Unge (Employment), Andréa Nicolin (Commercial Agreements), Frida Ställborn (Real Estate), Rebecka Weitzberg (IP) and counsel Maria Schultzberg (Tax).

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026